Skip to main content

Table 2 Sensitivity of XIAP depleted HCT-116, SW-620 and PC-3 tumor cells to various mechanistically distinct anti-cancer agents.

From: XIAP is not required for human tumor cell survival in the absence of an exogenous death signal

Drug

Cell line

EC50 (μM)

  

Untreated

Electroporated

Control siRNA

XIAP siRNA

Bortezomib

HCT-116

0.0075

0.0050

0.0047

0.0045

Doxorubicin

HCT-116

0.29

0.13

0.16

0.11

Etoposide

HCT-116

34.11

12.99

10.62

8.90

Paclitaxel

HCT-116

0.0083

0.0040

0.0024

0.0031

SAHA

HCT-116

2.014

0.98

0.67

0.51

Vincristine

HCT-116

0.015

0.0067

0.0035

0.0045

Bortezomib

SW-620

0.0036

0.0025

0.0025

0.0017

Doxorubicin

SW-620

0.79

0.657

0.48

0.43

Etoposide

SW-620

31.79

25.55

33.68

22.70

Paclitaxel

SW-620

0.017

0.0067

0.0086

0.0064

SAHA

SW-620

1.69

0.98

1.29

0.97

Vincristine

SW-620

0.035

0.013

0.031

0.0095

Bortezomib

PC-3

0.01

0.0063

0.0037

0.0041

Doxorubicin

PC-3

0.15

0.073

0.038

0.038

Etoposide

PC-3

41.96

16.58

26.13

16.76

Paclitaxel

PC-3

0.0028

0.00090

0.00067

0.00037

SAHA

PC-3

1.762

0.72

0.068

0.53

Vincristine

PC-3

0.0025

0.0016

0.0016

0.0016

  1. Potency (EC50) determinations from the dose response curves in Figure 5 (HCT-116 and SW-620) and Additional File 5 (PC3) were determined using non-linear regression and a least squares fit (GraphPad Prism software)
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us